The LncRNA H19/miR‐193a‐3p axis modifies the radio‐resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1

摘要

Abstract This study was designated to verify if the lncRNA H19/miR‐193a‐3p axis would play a regulatory role in the radio‐/chemo‐resistances of HCC cells through targeting PSEN1. Within the study, five human HCC cell lines were prepared, including Bel‐7402, HepG2, Hep3b, QGY‐7703, and SMMC‐7721. Moreover, docetaxel (DT), paclitaxel (Pt), vinorelbine (Vb), and 5‐fluorouracil (5‐Fu) were managed as the chemo‐therapeutics, and single‐dose X‐rays were performed as radio‐therapies. Besides, lncRNA H19 and miR‐193a‐3p were detected by qRT‐PCR and Western blot were implemented to quantify the expressional levels of PSEN1, Ku80, γ‐H2AX, and RAD51. Luciferase reporter gene assay was advanced to verify the targeted relationship between lncRNA H19 and miR‐193a‐3p. As a consequence, QGY‐7703 and Bel‐7402 were, respectively, the most radiation‐sensitive and radiation‐proof cell lines, and Bel‐7402 was associated with the highest resistances to DT, Pt, Vb, and 5‐FU. The restrained lncRNA H19 and over‐expressed miR‐193a‐3p expressions tended to significantly elevate the survival rate and proliferation of Bel‐7402 cells, when they were exposed to radiation and subject to chemo‐therapies. The lncRNA H19 was also found to directly target miR‐193a‐3p in inducing the HCC development. PSEN1 appeared to be subject to the modification of lncRNA H19 and miR‐193a‐3p in its acting on the survival rates and proliferative abilities of HCC cells. The lncRNA H19/miR‐193a‐3p/PSEN1 axis could be regarded as the treatment targets for HCC, so as to further improve the treatment efficacy of chemo‐ and radio‐therapies for HCC.